PCa Vaccine Followed by Docetaxel Beneficial
ANAHEIM, Calif.—Men with androgen independent prostate cancer (AIPC) who have received initial treatment with sipuleucel-T (Provenge) followed by docetaxel after progression of their disease may have prolonged survival, according to new findings presented here at the American Urological Association annual meeting.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.